The establishment of a bank of stored clinical bone marrow stromal cell products

• Published in: Journal of translational medicine 2012-02, Vol.10 (1), p.23-23, Article 23
• Main Authors: Sabatino, Marianna, Ren, Jiaqiang, David-Ocampo, Virginia, England, Lee, McGann, Michael, Tran, Minh, Kuznetsov, Sergei A, Khuu, Hanh, Balakumaran, Arun, Klein, Harvey G, Robey, Pamela G, Stroncek, David F
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aging - physiology; Antigens, CD34 - metabolism; Blood banks; Bone marrow; Bone Marrow Cells - cytology; Care and treatment; Cell Count; Cell Nucleus - metabolism; Cell Proliferation; Cells, Cultured; Colony-Forming Units Assay; Disease; Family medical history; FDA approval; Female; Health; Hepatitis; Humans; Inflammatory bowel diseases; Male; Manufacturing; Methodology; Methods; Middle Aged; Questionnaires; Stem cells; Stromal Cells - cytology; Time Factors; Tissue Banks; Tissue Donors; Tissue Preservation - methods; Transplantation; Viral infections; Young Adult
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/1479-5876-10-23

Bone marrow stromal cells (BMSCs) are being used to treat a variety of conditions. For many applications a supply of cryopreserved products that can be used for acute therapy is needed. The establishment of a bank of BMSC products from healthy third party donors is described. The recruitment of healthy subjects willing to donate marrow for BMSC production and the Good Manufacturing Practices (GMP) used for assessing potential donors, collecting marrow, culturing BMSCs and BMSC cryopreservation are described. Seventeen subjects were enrolled in our marrow collection protocol for BMSC production. Six of the 17 subjects were found to be ineligible during the donor screening process and one became ill and their donation was cancelled. Approximately 12 ml of marrow was aspirated from one posterior iliac crest of 10 donors; one donor donated twice. The BMSCs were initially cultured in T-75 flasks and then expanded for three passages in multilayer cell factories. The final BMSC product was packaged into units of 100 × 106 viable cells, cryopreserved and stored in a vapor phase liquid nitrogen tank under continuous monitoring. BMSC products meeting all lot release criteria were obtained from 8 of the 11 marrow collections. The rate of growth of the primary cultures was similar for all products except those generated from the two oldest donors. One lot did not meet the criteria for final release; its CD34 antigen expression was greater than the cut off set at 5%. The mean number of BMSC units obtained from each donor was 17 and ranged from 3 to 40. The production of large numbers of BMSCs from bone marrow aspirates of healthy donors is feasible, but is limited by the high number of donors that did not meet eligibility criteria and products that did not meet lot release criteria.